Lyvgen and BMS partner for Phase II lung cancer antibody trial

Lyvgen Biopharma has partnered with Bristol Myers Squibb (BMS ) to carry out a Phase II clinical trial of the former’s antibody, LVGN7409, plus docetaxel or nivolumab in advanced/metastatic non-small cell lung cancer (NSCLC) patients.